



A covetrus Company

29th June 2023

To our Valued Customers,

RE: To all veterinarians who have purchased Pentobarb 500 in the last five years and have product in stock

Further to our earlier communication on the 20th of June 2023 about possible potency concerns with Pentobarb 500, lab tests have now been completed and we are now able to provide an update on this issue. Specifically, testing has been carried out on the part packs directly involved and also unbroached packs from the same batches. In all cases, the results confirmed that all tested products were within the required technical specifications. Thus, it has been confirmed that the reported apparent inefficacy has not been caused by reduced levels of active ingredient in the batches that have been the subject of the investigation.

Advice received to date supports that existing product is fit for purpose. Additionally, Provet NZ has received new stock which is now available for purchase as required.

I want to extend my sincere thanks for the extra precautions you have taken and for your patience over the last week. For any further information, please don't hesitate to contact either myself or any of the Provet team. We are pursuing further stewardship recommendations from our industry partners and will be in contact as it becomes available.

Yours faithfully,

Adam Morris | Commercial Director, NZ | Provet NZ PTY LTD

M: +64 29 920 4445 E: adam.morris@covetrus.com



A covetrus Company

www.provet.co.nz

www.provet.co.nz

Auckland
T: 09 920 4440 F: 09 920 4459

Christchurch
T: 03 338 7400 F: 03 338 3088

Palmerston North
T: 06 355 5454 F: 06 355 5014